Cell and Gene Outsourcing

31. How Biosafety Assurance Can Be Both Rapid And Purposeful 2/24/2021

    A discussion on how novel treatment modalities such as viral vectors and the urgent need for SARS-CoV-2 treatments and vaccines are driving the advance of biopharma. 

32. Combining An MVA Technology Platform With Innovative Analytical Methods 7/21/2023

    Learn how this process development platform for MVA impacts vaccine manufacturing and supports the drug life cycle from process and analytical development through trials and commercialization.

33. AAV Analytics: Key Considerations When Developing A Clinical Program 4/25/2024

    Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.

34. Cell & Gene Therapy Development: Characterization Of Cellular Starting Material 6/21/2024

    Watch to gain valuable insights into the characterization of cellular source material for the development and manufacture of cell and gene therapy-based products.

35. Biopharmaceuticals Development And Manufacturing: Wide-Ranging Expertise And Vertically Integrated Service 11/17/2021

    The company’s wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art cGMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing.

36. Navigating The Complex Landscape Of Lentiviral Vector Quality Control 6/26/2025

    Explore the latest in lentiviral vector release testing, which covers biosafety, regulatory insights, and QC strategies to ensure patient safety and accelerate your path to clinic.

37. GLP And The Impact To Start Up Companies 4/18/2022

    Good Laboratory Practice is often used in laboratories and is necessary for specific investigations. What does it mean? And how can it help start-up companies? Watch this video to learn more.

38. Candidate Screening And Feasibility Studies For Viral Gene Therapies

    Create a simple, modular path to cGMP manufacturing that minimizes risk. Explore a strategic approach for early-stage development and how it can propel therapies to the clinic and the market.

39. A Transformative Journey From Research To Large-Scale Production 11/16/2023

    Learn about MilliporeSigma's journey to becoming a leader in clinical and commercial viral vector manufacturing and their support of cell and gene therapy innovators since the industry’s beginnings.

40. Pioneering Solutions That Turn Hope Into Reality

    The number of AAV-mediated therapies in clinical trials continues to rise, increasing demand for doses. A scalable platform is crucial to ensure a seamless transfer from pre-clinical to commercial.